Q2 2026 EPS Estimates for Blueprint Medicines Co. Boosted by Analyst (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities research analysts at Zacks Research boosted their Q2 2026 EPS estimates for Blueprint Medicines in a report issued on Monday, September 16th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings of $0.33 per share for the quarter, up from their previous forecast of $0.31. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The business had revenue of $138.20 million for the quarter, compared to the consensus estimate of $104.02 million. During the same period in the previous year, the firm earned ($2.19) EPS. The company’s quarterly revenue was up 139.9% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the stock. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Needham & Company LLC restated a “buy” rating and set a $130.00 target price on shares of Blueprint Medicines in a research note on Thursday, August 1st. JMP Securities reissued a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, June 7th. Barclays boosted their price target on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Finally, Robert W. Baird increased their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $91.68 on Thursday. Blueprint Medicines has a 12 month low of $43.89 and a 12 month high of $121.90. The stock has a market cap of $5.74 billion, a PE ratio of -19.06 and a beta of 0.58. The company’s fifty day moving average price is $98.29 and its 200-day moving average price is $98.96. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Amalgamated Bank raised its position in shares of Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after buying an additional 109 shares during the period. Van ECK Associates Corp raised its stake in shares of Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 131 shares during the period. EFG Asset Management North America Corp. boosted its position in shares of Blueprint Medicines by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after purchasing an additional 132 shares during the period. US Bancorp DE increased its holdings in Blueprint Medicines by 5.2% in the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 183 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in Blueprint Medicines by 5.2% in the second quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company’s stock valued at $527,000 after purchasing an additional 243 shares during the period.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Debra Durso-Bumpus sold 3,850 shares of the stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $111.20, for a total transaction of $428,120.00. Following the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,866,445.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Philina Lee sold 41,913 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the transaction, the insider now owns 34,729 shares in the company, valued at approximately $3,236,395.51. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,913 shares of company stock valued at $5,352,249. Insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.